Figure S6. End–of–treatment quit rates by treatment group and metabolizer group: Cross–ancestry wGRS tested. Odds ratios (OR) with 95% confidence intervals (CI) comparing the efficacy of varenicline versus the nicotine patch. Metabolizer–by–treatment interaction effects on end–of–treatment quit rates evaluated by the ratio of odds ratios (ORR) with 95% CI. Stratification by the cross–ancestry wGRS in the (A) merged EUR and AFR subset of the varenicline and nicotine patch treatment arms (*N*=679), (B) AFR subset (*N*=275), and (C) EUR subset (*N*=404) (slow: wGRS< 2.221, normal: wGRS≥2.221).